focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 118.00
Bid: 116.00
Ask: 120.00
Change: 0.00 (0.00%)
Spread: 4.00 (3.448%)
Open: 118.00
High: 118.00
Low: 118.00
Prev. Close: 118.00
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal of non-core product line

4 Apr 2024 07:00

RNS Number : 2155J
Eco Animal Health Group PLC
04 April 2024
 

4 April 2024

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Disposal of non-core product line

Disposal streamlines ECO Animal Health's product and pipeline focus

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces the disposal of ECOmectin® Horsepaste to ACME Drugs S.r.l in Italy ("ACME"), its long-term manufacturing partner, for a total consideration of €1.3m.

Continuing to streamline the business

ECO is focused on treatment and prevention of disease in pigs and poultry. ECOmectin® Horsepaste is a branded treatment for equine parasites based upon the ivermectin active ingredient and has for some time been non-core to the business. 

The Transaction

ACME has acquired all the marketing authorisations held by ECO for the ECOmectin® Horsepaste, together with the intellectual property, manufacturing and distribution arrangements and existing inventory ("the Transaction"). The marketing authorisations are principally within the UK and EU. In addition, ACME has been granted a trademark licence to market and sell the horse paste under the ECOmectin® brand. 

The total consideration for the Transaction is €1.3m; €500,000 was paid on signature of the sale and purchase agreement with an undertaking to pay two further payments of €400,000 each on the date which is 18 months after completion and 36 months after completion. These two elements of deferred consideration are unconditional and supported with a bank guarantee which will be put in place within 45 days.

The revenue derived from this business in the year ending 31 March 2024 was £814,000 (2023 £988,000).

Reinvesting to support our pipeline

The Board believes that the Transaction further streamlines ECOs focus on its core species of pigs and poultry and in particular on developing its highly innovative pipeline of vaccines and preventatives. It is intended that the funds received from the Transaction will be invested in research and development to support new product development.

David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "The disposal of ECOmectin® Horsepaste is in line with our stated intention of focusing on treatments and preventatives in pigs and poultry and this enables us to increase investment in our R&D pipeline. The brand and the broader business is a good fit for ACME Drugs S.r.l and we are pleased that the business will be taken forward by a committed owner.

"We continue to look for value accretive opportunities both within our portfolio and outside and for opportunities to reinvest in our R&D pipeline to support future growth."

-Ends-

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISSSIFIDELSEDL
Date   Source Headline
2nd Aug 20192:24 pmBUSHolding(s) in Company
2nd Aug 20191:12 pmBUSCirc re. Posting of Annual Report 2019
1st Aug 20192:17 pmBUSDirector/PDMR Shareholding
1st Aug 20197:00 amBUSTotal Voting Rights
1st Aug 20197:00 amBUSBlock listing Interim Review
8th Jul 20198:23 amBUSHolding(s) in Company
3rd Jul 20197:59 amBUSHolding(s) in Company
19th Jun 20197:00 amBUSFinal Results
5th Jun 201912:43 pmBUSHolding(s) in Company
29th May 20193:13 pmBUSDoc re. Change of Director Responsibilities
2nd Apr 20197:00 amBUSRegulatory Approval
20th Mar 20197:00 amBUSHolding(s) in Company
7th Mar 20197:05 amBUSDirector/PDMR Shareholding
7th Mar 20197:00 amBUSDirectorate change
5th Mar 20197:00 amBUSRegulatory Approval
13th Feb 20197:00 amBUSStatement Re ECO Animal Health and Ghent University Sign Poultry Vaccine Development Licencing Deal
7th Feb 201911:50 amBUSDirector/PDMR Shareholding
5th Feb 20199:58 amBUSHolding(s) in Company
5th Feb 20197:00 amBUSStatement re ECO Animal Health and University of Georgia sign second poultry vaccine development licencing deal
1st Feb 20197:00 amBUSTotal Voting Rights
1st Feb 20197:00 amBUSBlock listing Interim Review
31st Jan 201911:14 amBUSHolding(s) in Company
16th Jan 201910:48 amBUSDirector/PDMR Shareholding
27th Dec 20187:19 amBUSHolding(s) in Company
13th Dec 20183:00 pmBUSHolding(s) in Company
10th Dec 20187:00 amBUSHalf-year Report
5th Dec 201810:31 amBUSHolding(s) in Company
3rd Dec 20187:00 amBUSStatement re ECO Animal Health and Agrinnovation (Yissum) L.P. sign swine antimicrobial novel formulation development and licencing deal
27th Nov 20189:32 amBUSNotice of Results
19th Nov 20187:00 amBUSStatement re Joint poultry vaccine development licencing deal
7th Nov 20187:00 amBUSRegulatory Approval
1st Nov 20183:40 pmBUSHolding(s) in Company
1st Nov 20183:01 pmBUSHolding(s) in Company
26th Oct 20187:48 amBUSDirector/PDMR Shareholding
16th Oct 201811:26 amBUSHolding(s) in Company
20th Jul 20182:09 pmBUSDirector/PDMR Shareholding
18th Jul 201810:06 amBUSHolding(s) in Company
18th Jul 201810:01 amBUSHolding(s) in Company
10th Jul 20188:58 amBUSHolding(s) in Company
3rd Jul 20189:05 amBUSHolding(s) in Company
3rd Jul 20189:03 amBUSHolding(s) in Company
2nd Jul 20181:16 pmBUSDoc re. Block Listing Admission
2nd Jul 20187:00 amBUSFinal Results
1st May 20188:37 amBUSTotal Voting Rights
24th Apr 201811:22 amBUSHolding(s) in Company
12th Apr 201810:16 amBUSDirector/PDMR Shareholding
11th Apr 201812:03 pmBUSDirector/PDMR Shareholding
5th Apr 201812:02 pmBUSDirector/PDMR Shareholding - Replacement
5th Apr 201810:44 amBUSDirector/PDMR Shareholding
3rd Apr 20187:00 amBUSJoint Venture

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.